Oman oral solid dosage osd contract manufacturing market report Size, Share, Growth Drivers, Trends, Opportunities & Forecast 2025–2030
Description
Oman Oral Solid Dosage (OSD) Contract Manufacturing Market Overview
The Oman Oral Solid Dosage (OSD) Contract Manufacturing Market is valued at USD 210 million, based on a five-year historical analysis and proportional allocation from the regional healthcare contract manufacturing market size. This growth is primarily driven by the increasing demand for generic medications, the rise in chronic diseases such as diabetes and cardiovascular disorders, and the expansion of healthcare infrastructure across Oman. The market is further supported by the growing trend of outsourcing manufacturing processes by pharmaceutical companies to reduce operational costs, accelerate time-to-market, and access specialized expertise in advanced dosage technologies.
Key cities such as
Muscat
and
Salalah
dominate the market due to their strategic locations, robust logistics networks, and concentration of well-established healthcare facilities. Oman’s supportive regulatory environment and government initiatives—such as incentives for local pharmaceutical manufacturing and technology transfer programs—enhance the attractiveness of these cities for contract manufacturing. The presence of skilled labor, ongoing investments in modern manufacturing technologies, and the establishment of pharmaceutical clusters further contribute to their dominance.
In 2023, the Oman Ministry of Health introduced the
“Regulation for Registration and Control of Pharmaceutical Manufacturing Establishments, Ministerial Decision No. 41/2023”
, which mandates enhanced quality and safety standards for pharmaceutical products. This regulation requires contract manufacturers to comply with international Good Manufacturing Practices (GMP), undergo regular audits and inspections, and maintain comprehensive documentation to ensure traceability and product integrity. The operational scope includes licensing, periodic compliance reviews, and mandatory reporting of deviations, thereby improving the overall quality of oral solid dosage forms produced in Oman.
Oman Oral Solid Dosage (OSD) Contract Manufacturing Market Segmentation
By Type:
The market is segmented into various types of oral solid dosage forms, including tablets, capsules, powders, granules, and lozenges, gummies, pastilles, and others. Among these,
tablets and capsules
are the most widely used forms due to their convenience, stability, and ease of administration. The demand for powders and granules remains significant, especially in pediatric and geriatric segments where ease of swallowing is a concern. The lozenges and gummies segment is gaining traction, driven by increasing consumer preference for palatable and easy-to-administer dosage forms, particularly in nutraceutical and pediatric categories.
By End-User:
The end-user segmentation includes large pharmaceutical companies, medium and small pharmaceutical companies, generic pharmaceutical companies, hospitals, retail pharmacies, wholesalers, and online pharmacies.
Large pharmaceutical companies
dominate the market due to their extensive distribution networks, strong financial capabilities, and ability to invest in advanced manufacturing technologies. The rise of online pharmacies is also noteworthy, as they address the growing demand for convenient and accessible medication delivery, particularly post-pandemic. Hospitals and retail pharmacies continue to be significant channels for prescription and over-the-counter oral solid dosage products.
Oman Oral Solid Dosage (OSD) Contract Manufacturing Market Competitive Landscape
The Oman Oral Solid Dosage (OSD) Contract Manufacturing Market is characterized by a dynamic mix of regional and international players. Leading participants such as Gulf Pharmaceutical Industries (Julphar), Oman Pharmaceutical Products Co. LLC, Al Nahda Pharmaceutical Co. LLC, Dhofar Pharmaceutical Industries LLC, United Pharmaceutical Manufacturing Co. LLC, Muscat Pharmacy & Stores LLC, Al Jazeera Pharmaceutical Industries LLC, Oman Medical Products Co. LLC, Al Ahlia Pharmaceutical Manufacturing Co. LLC, Aster DM Healthcare, Badr Al Samaa Group, Al Hikma Pharmaceuticals PLC, Al Mufeed Pharmaceutical Co. LLC, Neopharma LLC, Oman Medical Supplies & Services Co. LLC contribute to innovation, geographic expansion, and service delivery in this space.
Gulf Pharmaceutical Industries (Julphar)
1980
Ras Al Khaimah, UAE
Oman Pharmaceutical Products Co. LLC
1990
Muscat, Oman
Al Nahda Pharmaceutical Co. LLC
2004
Muscat, Oman
Dhofar Pharmaceutical Industries LLC
1995
Salalah, Oman
United Pharmaceutical Manufacturing Co. LLC
2000
Muscat, Oman
Company
Establishment Year
Headquarters
Group Size (Large, Medium, or Small as per industry convention)
Annual Revenue (USD)
Revenue Growth Rate (%)
Market Penetration Rate (%)
Number of OSD Manufacturing Facilities
Production Capacity Utilization (%)
**Sources:**
[Source: ]
[Source: ]
[Source: ]
[Source: ]
Oman Oral Solid Dosage (OSD) Contract Manufacturing Market Industry Analysis
Growth Drivers
Increasing Demand for Generic Medications:
The demand for generic medications in Oman is projected to reach approximately 1.5 billion OMR in future, driven by rising healthcare costs and the need for affordable treatment options. The World Health Organization reports that generics account for over 80% of prescriptions in Oman, reflecting a significant shift towards cost-effective healthcare solutions. This trend is further supported by government initiatives aimed at promoting generic drug usage, enhancing the market for OSD contract manufacturing.
Expansion of Healthcare Infrastructure:
Oman’s healthcare expenditure is expected to increase to 1.2 billion OMR in future, reflecting a robust investment in healthcare infrastructure. The government is actively enhancing facilities and services, which is anticipated to boost the demand for oral solid dosage forms. This expansion includes the establishment of new hospitals and clinics, which will require a steady supply of pharmaceuticals, thereby driving the growth of the OSD contract manufacturing sector in the region.
Rising Prevalence of Chronic Diseases:
Chronic diseases such as diabetes and cardiovascular conditions are on the rise in Oman, with the Ministry of Health reporting that over 30% of the adult population is affected. This increase is expected to drive the demand for oral solid dosage forms, as they are commonly prescribed for long-term management of these conditions. Consequently, the OSD contract manufacturing market is positioned to benefit from this growing need for effective chronic disease management solutions.
Market Challenges
Stringent Regulatory Requirements:
The OSD contract manufacturing sector in Oman faces significant challenges due to stringent regulatory requirements imposed by the Ministry of Health. Compliance with Good Manufacturing Practices (GMP) is mandatory, and the cost of meeting these standards can be substantial. In future, it is estimated that compliance costs could account for up to 15% of total manufacturing expenses, posing a barrier for smaller manufacturers seeking to enter the market.
Limited Access to Advanced Technologies:
Many OSD manufacturers in Oman struggle with limited access to advanced manufacturing technologies, which can hinder production efficiency and product quality. According to industry reports, only 25% of local manufacturers have adopted state-of-the-art technologies, resulting in a competitive disadvantage. This gap in technological advancement can restrict the ability to innovate and meet the evolving demands of the pharmaceutical market.
Oman Oral Solid Dosage (OSD) Contract Manufacturing Market Future Outlook
The future of the Oman OSD contract manufacturing market appears promising, driven by increasing healthcare investments and a growing focus on generic medications. As the government continues to enhance healthcare infrastructure, the demand for OSD products is expected to rise significantly. Additionally, the integration of digital technologies in manufacturing processes will likely improve efficiency and product quality, positioning local manufacturers to better compete in both domestic and international markets.
Market Opportunities
Growth in Export Potential:
Oman’s strategic location and favorable trade agreements present significant export opportunities for OSD manufacturers. In future, exports of pharmaceutical products are projected to reach 300 million OMR, allowing local manufacturers to tap into international markets and diversify their revenue streams, enhancing overall market growth.
Collaborations with Local Pharmaceutical Companies:
Forming partnerships with local pharmaceutical firms can provide OSD manufacturers access to established distribution networks and market insights. Such collaborations are expected to increase market penetration and improve product availability, potentially boosting sales by an estimated 20% in future, thereby enhancing the competitive landscape.
Please Note: It will take 5-7 business days to complete the report upon order confirmation.
The Oman Oral Solid Dosage (OSD) Contract Manufacturing Market is valued at USD 210 million, based on a five-year historical analysis and proportional allocation from the regional healthcare contract manufacturing market size. This growth is primarily driven by the increasing demand for generic medications, the rise in chronic diseases such as diabetes and cardiovascular disorders, and the expansion of healthcare infrastructure across Oman. The market is further supported by the growing trend of outsourcing manufacturing processes by pharmaceutical companies to reduce operational costs, accelerate time-to-market, and access specialized expertise in advanced dosage technologies.
Key cities such as
Muscat
and
Salalah
dominate the market due to their strategic locations, robust logistics networks, and concentration of well-established healthcare facilities. Oman’s supportive regulatory environment and government initiatives—such as incentives for local pharmaceutical manufacturing and technology transfer programs—enhance the attractiveness of these cities for contract manufacturing. The presence of skilled labor, ongoing investments in modern manufacturing technologies, and the establishment of pharmaceutical clusters further contribute to their dominance.
In 2023, the Oman Ministry of Health introduced the
“Regulation for Registration and Control of Pharmaceutical Manufacturing Establishments, Ministerial Decision No. 41/2023”
, which mandates enhanced quality and safety standards for pharmaceutical products. This regulation requires contract manufacturers to comply with international Good Manufacturing Practices (GMP), undergo regular audits and inspections, and maintain comprehensive documentation to ensure traceability and product integrity. The operational scope includes licensing, periodic compliance reviews, and mandatory reporting of deviations, thereby improving the overall quality of oral solid dosage forms produced in Oman.
Oman Oral Solid Dosage (OSD) Contract Manufacturing Market Segmentation
By Type:
The market is segmented into various types of oral solid dosage forms, including tablets, capsules, powders, granules, and lozenges, gummies, pastilles, and others. Among these,
tablets and capsules
are the most widely used forms due to their convenience, stability, and ease of administration. The demand for powders and granules remains significant, especially in pediatric and geriatric segments where ease of swallowing is a concern. The lozenges and gummies segment is gaining traction, driven by increasing consumer preference for palatable and easy-to-administer dosage forms, particularly in nutraceutical and pediatric categories.
By End-User:
The end-user segmentation includes large pharmaceutical companies, medium and small pharmaceutical companies, generic pharmaceutical companies, hospitals, retail pharmacies, wholesalers, and online pharmacies.
Large pharmaceutical companies
dominate the market due to their extensive distribution networks, strong financial capabilities, and ability to invest in advanced manufacturing technologies. The rise of online pharmacies is also noteworthy, as they address the growing demand for convenient and accessible medication delivery, particularly post-pandemic. Hospitals and retail pharmacies continue to be significant channels for prescription and over-the-counter oral solid dosage products.
Oman Oral Solid Dosage (OSD) Contract Manufacturing Market Competitive Landscape
The Oman Oral Solid Dosage (OSD) Contract Manufacturing Market is characterized by a dynamic mix of regional and international players. Leading participants such as Gulf Pharmaceutical Industries (Julphar), Oman Pharmaceutical Products Co. LLC, Al Nahda Pharmaceutical Co. LLC, Dhofar Pharmaceutical Industries LLC, United Pharmaceutical Manufacturing Co. LLC, Muscat Pharmacy & Stores LLC, Al Jazeera Pharmaceutical Industries LLC, Oman Medical Products Co. LLC, Al Ahlia Pharmaceutical Manufacturing Co. LLC, Aster DM Healthcare, Badr Al Samaa Group, Al Hikma Pharmaceuticals PLC, Al Mufeed Pharmaceutical Co. LLC, Neopharma LLC, Oman Medical Supplies & Services Co. LLC contribute to innovation, geographic expansion, and service delivery in this space.
Gulf Pharmaceutical Industries (Julphar)
1980
Ras Al Khaimah, UAE
Oman Pharmaceutical Products Co. LLC
1990
Muscat, Oman
Al Nahda Pharmaceutical Co. LLC
2004
Muscat, Oman
Dhofar Pharmaceutical Industries LLC
1995
Salalah, Oman
United Pharmaceutical Manufacturing Co. LLC
2000
Muscat, Oman
Company
Establishment Year
Headquarters
Group Size (Large, Medium, or Small as per industry convention)
Annual Revenue (USD)
Revenue Growth Rate (%)
Market Penetration Rate (%)
Number of OSD Manufacturing Facilities
Production Capacity Utilization (%)
**Sources:**
[Source: ]
[Source: ]
[Source: ]
[Source: ]
Oman Oral Solid Dosage (OSD) Contract Manufacturing Market Industry Analysis
Growth Drivers
Increasing Demand for Generic Medications:
The demand for generic medications in Oman is projected to reach approximately 1.5 billion OMR in future, driven by rising healthcare costs and the need for affordable treatment options. The World Health Organization reports that generics account for over 80% of prescriptions in Oman, reflecting a significant shift towards cost-effective healthcare solutions. This trend is further supported by government initiatives aimed at promoting generic drug usage, enhancing the market for OSD contract manufacturing.
Expansion of Healthcare Infrastructure:
Oman’s healthcare expenditure is expected to increase to 1.2 billion OMR in future, reflecting a robust investment in healthcare infrastructure. The government is actively enhancing facilities and services, which is anticipated to boost the demand for oral solid dosage forms. This expansion includes the establishment of new hospitals and clinics, which will require a steady supply of pharmaceuticals, thereby driving the growth of the OSD contract manufacturing sector in the region.
Rising Prevalence of Chronic Diseases:
Chronic diseases such as diabetes and cardiovascular conditions are on the rise in Oman, with the Ministry of Health reporting that over 30% of the adult population is affected. This increase is expected to drive the demand for oral solid dosage forms, as they are commonly prescribed for long-term management of these conditions. Consequently, the OSD contract manufacturing market is positioned to benefit from this growing need for effective chronic disease management solutions.
Market Challenges
Stringent Regulatory Requirements:
The OSD contract manufacturing sector in Oman faces significant challenges due to stringent regulatory requirements imposed by the Ministry of Health. Compliance with Good Manufacturing Practices (GMP) is mandatory, and the cost of meeting these standards can be substantial. In future, it is estimated that compliance costs could account for up to 15% of total manufacturing expenses, posing a barrier for smaller manufacturers seeking to enter the market.
Limited Access to Advanced Technologies:
Many OSD manufacturers in Oman struggle with limited access to advanced manufacturing technologies, which can hinder production efficiency and product quality. According to industry reports, only 25% of local manufacturers have adopted state-of-the-art technologies, resulting in a competitive disadvantage. This gap in technological advancement can restrict the ability to innovate and meet the evolving demands of the pharmaceutical market.
Oman Oral Solid Dosage (OSD) Contract Manufacturing Market Future Outlook
The future of the Oman OSD contract manufacturing market appears promising, driven by increasing healthcare investments and a growing focus on generic medications. As the government continues to enhance healthcare infrastructure, the demand for OSD products is expected to rise significantly. Additionally, the integration of digital technologies in manufacturing processes will likely improve efficiency and product quality, positioning local manufacturers to better compete in both domestic and international markets.
Market Opportunities
Growth in Export Potential:
Oman’s strategic location and favorable trade agreements present significant export opportunities for OSD manufacturers. In future, exports of pharmaceutical products are projected to reach 300 million OMR, allowing local manufacturers to tap into international markets and diversify their revenue streams, enhancing overall market growth.
Collaborations with Local Pharmaceutical Companies:
Forming partnerships with local pharmaceutical firms can provide OSD manufacturers access to established distribution networks and market insights. Such collaborations are expected to increase market penetration and improve product availability, potentially boosting sales by an estimated 20% in future, thereby enhancing the competitive landscape.
Please Note: It will take 5-7 business days to complete the report upon order confirmation.
Table of Contents
81 Pages
- 1. Oman oral solid dosage osd contract manufacturing Size, Share, Growth Drivers, Trends, Opportunities & – Market Overview
- 1.1. Definition and Scope
- 1.2. Market Taxonomy
- 1.3. Market Growth Rate
- 1.4. Market Segmentation Overview
- 2. Oman oral solid dosage osd contract manufacturing Size, Share, Growth Drivers, Trends, Opportunities & – Market Size (in USD Bn), 2019–2024
- 2.1. Historical Market Size
- 2.2. Year-on-Year Growth Analysis
- 2.3. Key Market Developments and Milestones
- 3. Oman oral solid dosage osd contract manufacturing Size, Share, Growth Drivers, Trends, Opportunities & – Market Analysis
- 3.1. Growth Drivers
- 3.1.1. Increasing demand for generic medications
- 3.1.2. Expansion of healthcare infrastructure
- 3.1.3. Rising prevalence of chronic diseases
- 3.1.4. Cost-effective manufacturing solutions
- 3.2. Restraints
- 3.2.1. Stringent regulatory requirements
- 3.2.2. Limited access to advanced technologies
- 3.2.3. Competition from established players
- 3.2.4. Fluctuating raw material prices
- 3.3. Opportunities
- 3.3.1. Growth in export potential
- 3.3.2. Collaborations with local pharmaceutical companies
- 3.3.3. Adoption of innovative manufacturing processes
- 3.3.4. Increasing focus on sustainability
- 3.4. Trends
- 3.4.1. Shift towards personalized medicine
- 3.4.2. Integration of digital technologies in manufacturing
- 3.4.3. Rise of contract manufacturing partnerships
- 3.4.4. Emphasis on quality assurance and compliance
- 3.5. Government Regulation
- 3.5.1. GMP compliance requirements
- 3.5.2. Import/export regulations for pharmaceuticals
- 3.5.3. Pricing regulations for generic drugs
- 3.5.4. Environmental regulations impacting manufacturing
- 3.6. SWOT Analysis
- 3.7. Stakeholder Ecosystem
- 3.8. Competition Ecosystem
- 4. Oman oral solid dosage osd contract manufacturing Size, Share, Growth Drivers, Trends, Opportunities & – Market Segmentation, 2024
- 4.1. By Product Type (in Value %)
- 4.1.1. Tablets
- 4.1.2. Capsules
- 4.1.3. Powders
- 4.1.4. Granules
- 4.1.5. Others
- 4.2. By End-User (in Value %)
- 4.2.1. Large Pharmaceutical Companies
- 4.2.2. Medium & Small Pharmaceutical Companies
- 4.2.3. Generic Pharmaceutical Companies
- 4.2.4. Hospitals
- 4.2.5. Retail Pharmacies
- 4.3. By Distribution Channel (in Value %)
- 4.3.1. Direct Sales
- 4.3.2. Distributors
- 4.3.3. E-commerce
- 4.4. By Product Formulation (in Value %)
- 4.4.1. Immediate Release
- 4.4.2. Extended Release
- 4.4.3. Controlled Release
- 4.5. By Packaging Type (in Value %)
- 4.5.1. Blister Packs
- 4.5.2. Bottles
- 4.5.3. Strip Packs
- 4.6. By Region (in Value %)
- 4.6.1. North Oman
- 4.6.2. South Oman
- 4.6.3. East Oman
- 4.6.4. West Oman
- 4.6.5. Central Oman
- 5. Oman oral solid dosage osd contract manufacturing Size, Share, Growth Drivers, Trends, Opportunities & – Market Cross Comparison
- 5.1. Detailed Profiles of Major Companies
- 5.1.1. Gulf Pharmaceutical Industries (Julphar)
- 5.1.2. Oman Pharmaceutical Products Co. LLC
- 5.1.3. Al Nahda Pharmaceutical Co. LLC
- 5.1.4. Dhofar Pharmaceutical Industries LLC
- 5.1.5. United Pharmaceutical Manufacturing Co. LLC
- 5.2. Cross Comparison Parameters
- 5.2.1. Annual Revenue (USD)
- 5.2.2. Number of OSD Manufacturing Facilities
- 5.2.3. Market Penetration Rate (%)
- 5.2.4. Quality Compliance Rate (%)
- 5.2.5. R&D Investment as % of Revenue
- 6. Oman oral solid dosage osd contract manufacturing Size, Share, Growth Drivers, Trends, Opportunities & – Market Regulatory Framework
- 6.1. GMP Standards
- 6.2. Compliance Requirements and Audits
- 6.3. Certification Processes
- 7. Oman oral solid dosage osd contract manufacturing Size, Share, Growth Drivers, Trends, Opportunities & – Market Future Size (in USD Bn), 2025–2030
- 7.1. Future Market Size Projections
- 7.2. Key Factors Driving Future Market Growth
- 8. Oman oral solid dosage osd contract manufacturing Size, Share, Growth Drivers, Trends, Opportunities & – Market Future Segmentation, 2030
- 8.1. By Product Type (in Value %)
- 8.2. By End-User (in Value %)
- 8.3. By Distribution Channel (in Value %)
- 8.4. By Product Formulation (in Value %)
- 8.5. By Packaging Type (in Value %)
- 8.6. By Region (in Value %)
- Disclaimer
- Contact Us
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
